Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Summarize this article with:
SA Transcripts157.38K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Pfizer Inc. (PFE) Q4 2026 Guidance Call December 16, 2025 8:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations OfficerAlbert Bourla - Chairman of the Board & CEODavid Denton - Executive VP & CFO Conference Call Participants Alexandria Hammond - Wolfe Research, LLCTerence Flynn - Morgan Stanley, Research DivisionDavid Risinger - Leerink Partners LLC, Research DivisionEvan Seigerman - BMO Capital Markets Equity ResearchLouise Chen - Scotiabank Global Banking and Markets, Research DivisionGeoffrey Meacham - Citigroup Inc., Research DivisionJason Gerberry - BofA Securities, Research DivisionMohit Bansal - Wells Fargo Securities, LLC, Research DivisionChristopher Schott - JPMorgan Chase & Co, Research DivisionCourtney Breen - Sanford C. Bernstein & Co., LLC., Research DivisionCarter Gould - Cantor Fitzgerald & Co., Research DivisionKerry Holford - Joh. Berenberg, Gossler & Co. KG, Research DivisionVamil Divan - Guggenheim Securities, LLC, Research DivisionChristopher LoBianco - TD Cowen, Research DivisionAsad Haider - Goldman Sachs Group, Inc., Research Division Presentation Operator A good day, everyone, and welcome to Pfizer's analyst and investor call to review the full year 2026 financial guidance. Today's call is being recorded. At this time I would like to turn the call over to Francesca DeMartino, chief investor relations officer and senior vice president. Please go ahead, ma'am. Francesca DeMartinoChief Investor Relations Officer Good morning, and welcome to Pfizer's 2026 financial guidance call. I'm Francesca DeMartino, chief investor relations officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at Pfizer.com. Earlier this morning we released our 2026 financial guidance via a press release that is available at our website, Pfizer.com. I'm doing today by Dr. Albert Bourla, our Chairman and CEO, and Dave Denton, our CEO. Albert and Dave have prepared remarks and then we'll open the call for questions. Before you get started I want to remind you that we'll be making forward-looking